Drug intelligence / Profile preview

naftifine

Development stage
Approved
Lead developer
Sandoz
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Topical
01

Overview

Naftifine is a synthetic, broad-spectrum antifungal agent of the allylamine class used topically to treat fungal skin infections such as tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) caused by dermatophytes including *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, and *Epidermophyton floccosum*. It was invented at the Sandoz Research Institute in Vienna and was the first successful antifungal medication of its class. Naftifine acts primarily by inhibiting squalene monooxygenase (squalene 2,3-epoxidase), an enzyme involved in sterol biosynthesis. This inhibition leads to decreased ergosterol production—an essential component of fungal cell membranes—and accumulation of squalene within fungal cells. The drug exhibits fungicidal activity against dermatophytes and molds and fungistatic activity against yeasts; it also has antibacterial and anti-inflammatory properties[3][5][6][8].

Brand names
NaftinExoderilNaftin Pump
Other names
naftifine hydrochloride
02

Targets

MmpL3 (Mycobacterial membrane protein Large 3)SQLE (Squalene monooxygenase)

Beyond the preview

Go deeper on naftifine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naftifine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call